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Abstract
Heart disease includes an array of cardiovascular diseases causing 25% of all
deaths annually in the United States. Patients who live with heart disease experience
significantly decreased quality of life. While current treatments on the market aim at
improving heart function and cardiovascular efficiency, none are able to restore
functionality to native levels. Tissue engineered approaches are becoming increasingly
viewed as the definitive treatment to increasing longevity and quality of life of patients
affected by heart disease. While stem cell therapies have immense potential, clinical
application is still largely unsuccessful in generating healthy myocardium in patients.
This study aims to differentiate and characterize human embryonic, induced pluripotent,
and adipose derived stem cells into cardiomyocytes to engineer an electrically conductive
construct for heart disease patients.
Action potentials of embryonic, and induced pluripotent derived cardiomyocytes
were measured using Nanion’s automated patch clamp system in order to attain baseline
measurements. Current and voltage clamp configurations were used under physiological
conditions and electrical signals were sampled every 15 seconds. In addition, two and
three dimensional co-culture studies were performed using adipose-derived and
embryonic-derived cardiomyocytes. The cells were seeded within an agarose gel and on
6-well plates at a 2:1 ratio. Samples were then measured using the automated patch clamp
system after seven days of culture and stained for connexin-43 and desmin using
immunofluorescence. Lastly, multielectrode array measurements readings were
performed using embryonic derived cardiomyocytes to verify the patch clamp data.

ii

Results showed differentiated induced pluripotent stem cells produced action
potentials almost identical to ventricular cardiomyocytes. No action potential readings
were able to be recorded for the three dimensional cultures, however physiologically
relevant action potentials were measured in the 2D co-culture groups. Additionally, the
3D co-culture samples all stained positive for connexin-43 and desmin verifying that the
differentiated cells possessed unique cardiomyocyte markers. Future studies should
devote more effort into differentiating successful cardiac pacemaker cells from adipose
derived stem cells.
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Chapter 1: Literature Review

1

1.1 Structure of the Cardiovascular System
The cardiovascular system functions to supply nutrients and remove waste from
tissues throughout the body. In order to efficiently accomplish this, the conduction
system is divided into two parts, the systemic and pulmonary circuits. The pulmonary
circuit serves to oxygenate blood and remove carbon dioxide via the lungs while the
systemic circuit distributes oxygenated blood to tissues throughout the body. The heart is
at the center of these circuits functioning as a pump to continually circulate the necessary
amount of blood. Comprising of two halves, the left side of the heart connects to the
systemic circuits providing oxygenating blood to tissues while the right side connects to
the pulmonary circuit disposing of cellular byproduct via the lungs. The heart functions
through systematic contraction and relaxation cycles able to distribute over 2000 gallons
of blood per day.1

Figure 1: Diagram of Systemic and Pulmonary Circuit. 1

1
2

Image taken from tes.com
Image taken from Interactive-biology.com
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1.1.1

Tissue Layers of the Heart Wall and The Pericardial Cavity
The heart is comprised of three separate tissue layers which structurally reflect the

physical requirement functionalities that cardiac tissue must undergo. The outermost
layer is the pericardium which is the membrane encompassing the heart. This is a double
membrane sac composed of an outmost fibrous layer and an inner serous membrane. This
encloses the pericardial cavity containing pericardial fluid. The pericardium functions to
anchor the heart to the mediastinum and prevents the heart from overfilling with blood.
The serous layer is divided into two layers called the visceral and parietal pericardium
functioning to prevent friction during repeated cardiac cycles.
The visceral pericardium corresponds to the outermost layer of the heart known as
the epicardium. This layer is primarily comprised of fibrous tissue and functions as a
protective layer. The middle layer of the heart is comprised of cardiac muscle tissue and
is the predominate layer of the cardiac wall. The thickness of the myocardium is
reflective of heavy loads that the heart undergoes to effectively circulate blood
throughout the body. The innermost layer is the endocardium containing a single layer of
endothelial cells providing a lining for blood cells coming in contact with tissue surfaces.
Additionally, this layer also extends to the surface of heart valves as well as providing the
structure for which the cardiac conduction system is regulated.2

3

1.1.2

Chambers and Valves of the Heart
The heart is divided into four chambers each half containing two chambers each.

The upper chambers are known as the atria while the bottom half of the heart contains the
ventricles. Each chamber of the heart is separated by heart valves which act as barriers
between the chambers. The atria is the first chamber of the heart in which blood is
received from either circuit. The right atria receives deoxygenated blood via the systemic
circuit while the left atria receives oxygenated blood through the pulmonary circuit. In
systole, the atria relax and fill with blood which the atrioventricular valves separating the
atria and ventricle remains closed. Simultaneously, both semilunar valves open and the
ventricles contract, expelling all contents within the chamber. The atrioventricular valves
will then open allowing the atria to contract and eject the contents into the ventricular
chambers. The structure of the chambers is noticeably different as the ventricles have
substantially thicker walls than the atria. This is due to the elevated forces the ventricles
receive as the mechanical pressure required to eject fluid out of the heart and through the
extensive length of the cardiovascular system is much greater than that of the atria which
only serve to expel fluid to the adjacent ventricles.
Furthermore, the valves play an important role in maintaining correct fluid flow
throughout the cardiovascular system. The valves prevent backflow between chambers
which would impede the hearts ability to efficiently eject blood. The atrioventricular
valves contain leaflets that are attached to papillary muscles via chordae tendineae
preventing the valves from inversion. Similarly, the semilunar valves prevent backflow
from the arteries into the ventricles. However unlike the atrioventricular valves, the

4

leaflets do not have attachments to the heart muscle as they function as a valve similar to
a vein.2 The structure of the atria and ventricles as well as the valves can be observed in
figure 2.

2

Figure 2: Diagram of the Heart

1.1.3

Cardiac Conduction System of the Heart
In order to pump blood efficiently, the heart contains its own unique cardiac

conduction system. The atria and ventricles must contract at precise temporal intervals
otherwise blood cannot be properly ejected from the heart. The cardiac conduction
system is designed such that electrical signals travel from the base to the apex of the heart
with appropriate delays in signal between specific junctions. The conduction system is
comprised of the sinoatrial node, atrioventricular node, the bundle of His and the purkinje
fibers that extend throughout the apex of the heart. This system carries the initial impulse
which stimulates the entire myocardium extending out to the epicardium.
2

Image taken from Interactive-biology.com
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To initialize a signal, specialized cardiac muscles cells within the sinoatrial node
(SA node) located in the wall of the right atrium initialize the electrical impulse by
sending a signal to the atrioventricular node (AV node) located in the interatrial septum
via internodal pathways. The signal then continues down through the left and right bundle
branches to the apex of the heart via the purkinje fibers. Electrical impulses travel at
varying velocities throughout this pathway to maximize stroke volume. The time elapsed
for signal travel between the SA and AV node is much longer than signal travel time of
the bundle branches and purkinje fibers (approximately 0.5 m/sec vs 4 m/sec).3 This
signal delay allows for complete depolarization of the atria resulting in proper emptying
of atrial contents into the ventricles. Insufficient delay would cause simultaneous
contraction of the atria and ventricles resulting in improper emptying and backflow. In
addition, atrial and ventricular pathways are only connected through the AV node, which
acts as a buffer preventing improper signal propagation between atria and ventricles. This
pathway can be viewed in figure 3.

Figure 3: Diagram of the Cardiac Conduction System3

3

Image taken from Boundless.com
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1.2

Cellular Anatomy of Cardiomyocytes

1.2.1

Varieties of Cardiomyocytes
There are two main types of myocytes found in the heart which distinguishing

characteristics. The majority of cells in the myocardium are non-spontaneous which are
present in both the atria and ventricles. These cells have the capability of propagating
electrical signals however they are unable to spontaneously contract. The second type of
cell is a cardiac pacemaker cell. These cells have special transmembrane proteins that
allow them to spontaneous contract thus exciting neighboring cells creating an action
potential that is carried throughout the myocardium. Most cardiac pacemaker cells are
located in the SA and AV nodes and thus are responsible for generating an electrical
impulse.
Muscle contraction due to signal conduction can only be achieved due to unique
properties of cardiomyocytes on a cellular level. The anatomy is a direct representation of
the rigorous environment of the cell. On a microscopic level, cardiomyocytes appear to
be a branching, interconnected network of cells more rectangular in appearance from the
spindle shaped smooth muscle cells and smaller in length and width from skeletal muscle
(0.1 mm by 0.2 mm).

7

Figure 4: Microscopic image of cardiomyocytes zoomed
to show detail of intercalated discs4

Cardiomyocytes contain a single nucleus, yet multiple mitochondria, providing
additional energy for many cycles of cellular contraction. Furthermore, striations can be
viewed under the microscope as light and dark bands in parallel arrangements of actin
and myosin throughout the cell. However, the most defining features that separate
cardiomyocytes from other cells are the presence of intercalated discs (figure 4) which
comprise a variety of cellular junction that serve a variety of different functions.
Intercalated discs are classically understood to have three main functional zones: the
fascia adherens, desmosomes and gap junctions.4
1.2.2

Intercellular Junctions in Cell Signaling
The fascia adherens transmits mechanical forces between cells and provides an

anchor site for actin filaments to attach to proteins within the fascia adherens.
Additionally, this region contains catenin proteins which allows for cadherins to attach
forming multiple intracellular contacts. Coupled with this subcellular domain are
4

Image taken from humanpathology.com
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desmosomes comprising the second zone which act as a “glue” preventing cellular
separation during contraction through robust bonding of intermediate filaments between
cellular cytoskeletons. Furthermore, the third and most critical regions are comprised of
gap junctions, providing a means of transcellular signaling that provides the platform on
which transmitting electrical signals are possible. Gap junctions narrow the space
between adjacent cells from approximately 25 nm to 3 nm at the site of the junction
proteins. These domains are made up of ion channels known as connexons
(predominately Cx40 and Cx43) which form a pore through precise alignment of the Cx
proteins between adjacent cells. Typically six connexins are present at each intercalated
disc which allow for ample passageway between cells to propagate strong action
potentials across cell membranes via ion transfer (Na, K, Ca).4
1.2.3

Cellular Contraction and The Sliding Filament Model
In cardiac muscle, contraction occurs through what is known as excitation

contraction coupling. This process converts an electrical stimulus to a mechanical
response. Excitation contraction coupling is dependent in cardiac muscle tissue on an
event called calcium induced calcium release (CICR) by which the presence of calcium
ions further stimulate the release of calcium ions.
When an action potential is generated, sodium influx through the cell membrane
and into t-tubules stimulates the activation of a receptor called dyhydropyradine channel
or commonly known as L-type calcium channel. Increased concentration of sodium ions
activates this channel to open allowing calcium to enter the cell. As a result of elevated
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intracellular calcium levels, ryanodine channels in the sarcoplasmic reticulum are
activated and additional calcium is transported into the cytosol.
Increased intracellular calcium levels is critical in muscle contractions and
especially when creating a sustained contraction as seen in the ventricles. Calcium
activates contraction by binding to troponin on the actin filament. Tropomyocin a helical
protein wrapped around actin is released and the myosin binding sites are exposed for the
myosin head to attach. Upon adenine triphosphate hydrolysis the myosin head contracts
pulling the actin across laterally. This reaction takes place at many different locations and
collectively is able to stimulate an entire fiber to contract. This is shown in figure 5 and is
known as the sliding filament model.5

Figure 5: Diagram of the sliding filament model5

1.3

Electrophysiology of the Cell

1.3.1

Voltage Gated Ion Channels
Electrically excitable cells must all possess conduits in which electrical current

may flow. When speaking in terms of cellular physiology, electrical current manifests
5

Image taken from thealevelbiologist.co.uk
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itself through positively or negatively charged ion flow. To achieve ample ion transfer
between cells cardiomyocytes possess special structures for cell to cell contact as
discussed previously as well as voltage gated ion channels that allow for the transfer of
extracellular ions.
The most predominate voltage gated channels found on most electrically excitable
cells are sodium and potassium channels. These channels are integral membrane proteins
comprised of alpha and beta subunits spanning six membrane-bound segments as shown
in figure 6. The S4 segment is highly conserved and is responsible for sensing the voltage
within the channel. When stimulated by a transmembrane change in voltage, this unit
moves slightly towards the extracellular side of the membrane to become more permeable
to ion flow.

Figure 6: Voltage gated ion channel domains spanning the cell
membrane6

There are three states of voltage gated ion channels: closed, open, and inactivated.
The state of the channel is dependent upon the voltage of the environment as the channels
6

Image taken from Nature
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will open or close in response to a change in transmembrane voltage. Inactive states are
those which can be seen at the peak of an action potential where a channel will plug the
lumen to prevent further ion flow. Furthermore, ion channels posses selectivity filters that
are composed of negatively or positively charged amino acids depending on the channel
type. Sodium channels often have negatively charged residues to attract the positively
charged sodium. Channels are additionally size selective to restrict ion flow. Sodium
channels do not allow potassium or calcium ions to pass as the pore diameter is too
small.4
In the case of pacemaker cells, specialized membrane proteins allow the cell to
excite itself without the need for external stimulation. This occurs due to leaky sodium
channels that allow the steady passage of sodium through the cell causing the initial
change in membrane potentials. Additionally, antiporter proteins known as the sodiumcalcium exchanger (NCX) operates by using the electrochemical gradient found in the
extracellular solution to allow sodium ions to flow intracellularly in exchange for
extracellular transport of calcium ions. The NCX transports one calcium ion for every
three sodium ions thereby resulting in a net positive influx of positive charge. This causes
the cell to further depolarize itself until it reaches a set voltage in which an irreversible
and complete depolarization occur. The NCX also has the ability to reverse transportation
and does so briefly following each action potential as intracellular sodium concentration
must be reduced and calcium increased until L type calcium channels are activated.6
However, calcium concentration is not as high as a typical cardiomyocyte since
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pacemaker cells do not need to sustain mechanical contraction and is reflected in the
action potential which can be seen in figure 7.

Figure 7: Action potential diagram of a cardiac pacemaker cell7

1.3.2

Stages of Action Potentials in Cardiomyocytes
In ventricular cardiomyocytes, action potentials are unique in that constant

voltage in necessary in sustaining contraction between cells. Unlike action potentials of
neurons or cardiac pacemaker cells, the action potential is drawn out due to CICR which
can be seen in figure 8. Classically, there are five regions of the cardiomyocyte action
potential (labeled 0-4) which represents the main stages in generating the action potential.

7

Taken from classes.midlandstech.edu
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Figure 8: Action potential of a ventricular cardiomyocyte8

All electrically excitable cells have a resting membrane potential due to the
different concentration of ions across the membrane potential which is represented by
stage four in the graph. Typically, sodium ions are present in higher in extracellular
concentrations and conversely, potassium ions are more abundant in the intracellular
space. However, the ratio of sodium to potassium ions across membrane is not 1:1 and
therefore a resulting charge is placed across the membrane. Due to a much higher
concentration of sodium across the membrane, as seen in ventricular cardiomyocytes,
resting membrane potential is set at around -90 mV.
Action potentials are generated when ion concentration changes from its natural
levels causing a rapid change of membrane potential. Phase 0 in the graph represents an
influx of sodium ions into the cell resulting in a rapid depolarization of the membrane.
Action potentials are unidirectional, irreversible and are typically known as all or nothing
events because once transmembrane voltage reaches a certain threshold, complete and
8

Image taken from pathophys.org
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rapid depolarization occurs. Once transmembrane voltage reaches -50mV due to rapid
sodium influx, repolarization begins to occur as potassium and chloride ions move out of
the cell reducing intracellular charge, this happens slowly and potassium efflux occurs
over the course of phases 1 and 2.
Phase 2 is the most notable and unique in that a sustained calcium influx occurs in
response to L-type calcium channels opening as a result of extreme depolarization and an
outward efflux of potassium ions. The final stage is repolarization which results from
calcium channels closing and a delayed rapid potassium efflux across the membrane
dropping the membrane voltage back to its resting potential. As this process occurs, ion
movement flows both across the cell membrane and between cells through connexins
causing the propagation of action potentials throughout the myocardium.7
While all cardiomyocytes are able to respond and propagate action potentials,
action potentials generated by ventricular cardiomyocytes are substantially different than
those seen in cardiac pacemaker cells as illustrated in figure 7. While ventricular
cardiomyocytes must sustain contraction for complete blood ejection from the ventricle,
pacemaker cells must provide the initial signal for ventricular cells to respond. While
pacemaker cells contract on some level, they do not contract on the magnitude of
ventricular cardiomyocytes, hence a lack of a plateau upon depolarization. Additionally,
these cells have a much slower initiation due to slow depolarization via the NCX protein
and thus a much longer phase 4 region as can be viewed in image 7.
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1.3.3

Modeling Electrophysiology Using Circuitry
The paradigm of modern electricity to the layperson consists of a circuit

composed of various components that acts as a conduit for electrons to pass through.
However many cells in the body also act as circuitry to perform many critical functions
for survival. Neural networks of cells pass billions of signals daily to perform motor or
sensory functions. Cardiac cells transmit current to pump blood throughout the body.
Regardless of cell type or function, all electrically excitable cells can be modeled using
traditional circuitry diagrams.
In electrophysiological modeling, resistors are used to model ion channels
through which ions or current flows as shown in figure 9. It is convenient to discuss
currents as conductance (the inverse of resistance) as conductance sums in parallel
circuits. When modeling several ion channels open simultaneously, the total conductance
is simply the sum of all individual channel conductances. Additionally, the cellular
membrane acts as a capacitor due to the membrane thickness, and its good insulator
properties.

Figure 9: Physical representation of a circuit modeling the cell membrane9

9

Image taken from Axon Patch Clamp Guide
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Capacitance is defined as the ability to store charge when a voltage is present
between two points. In terms of cellular electrophysiology, capacitance can be neglected
when voltage remains constant across the membrane. If voltage clamping, transient
capacitance currents can be measured for a brief time while stepping up to a new voltage
value, appearing as an artifact in the graph.
Establishing directional conventions for vector measurements is crucial when
measuring action potentials. Voltage defined by the electrical potential with respect to
one spatially defined position can be represented using a battery which can be reversed
depending on the microstate of the cell at any given time. Voltage can be applied globally
across the cell membrane or locally through any given ion channel. For example,
measuring a cardiomyocyte sodium channel in a grounded state where extracellular
sodium concentrations are approximately 10 fold higher than intracellular concentrations
would approximate to a +90 mV battery in a physiological normal cell. Conversely
potassium channels in a resting state would equate to approximately -90 mV in
physiologically normal cells.8 When discussing the resting membrane potential, defined
as voltage of the inner membrane with respect to the outer membrane in an unexcited
state, it is important to remember that this condition represents a steady state system in
which no net ion flow occurs across the membrane. Furthermore, representing positive
ion influx across the cell membrane is conventionally established as negative current.
Conversely, positive ion efflux through the membrane would be considered positive
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current. If voltage clamping a mature healthy cell, one would expect to see a large
negative current followed by a positive current until complete repolarization occurs.
1.3.4

Using Patch Clamping Techniques to Characterize Cellular
Electrophysiology
Measuring action potentials in cells has been around since the late 1940s when

giant squid axons were voltage clamped to measure trans-membrane current. These
experiments were the foundation for Hodgkin and Huxley’s action potential model and
became the basis for cellular electrophysiology. Since then, measuring action potentials
has become more refined and precise since the development of the patch clamp
technique.
Patch clamping was developed in the late 1970s and into the early 80s by Erwin
Neher and Bert Sakmann who later went on to receive the Nobel Prize in Physiology and
Medicine in 1991. This laboratory technique allows high-resolution current recordings of
single or multiple ion channels on cell surface membranes. Since its inception, there have
arisen many variations on this technique but in principle its recording methodology
remains unchanged.
The traditional or cell attached patch clamp technique is used to study single ion
channels or a small patch of channels on the cell surface membrane As evidenced in
figure 10, a glass micropipette filled with bath solution is placed on the cell membrane
and suction is applied to form a highly resistant seal in the gigaohm range. This tight seal
is essential in insulating the cell patch as all ions must flow from the ion channel into the
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pipette tip. Ion flux is measured using a silver chloride electrode connected to an
operational amplifier and a bath electrode is used as a reference node.
Once the setup is complete, the user may clamp the current or voltage at the
desired level depending on the cell type. If clamping the voltage, the user inputs the
appropriate voltage and the membrane voltage will be measured and compared to the
input voltage. If the two values are different, the amplifier will inject current into the cell
until the membrane potential equals the user input voltage. Conversely, when measuring
action potentials current is clamped and through the same process, voltage is measured
across the cell membrane.

Figure 10: Traditional patch clamp setup diagram10

There are a couple of variations of the cell attached patch clamp method including
the inside out and outside in patch clamping techniques. The inside out patch involves
removing a section of membrane from the cell using the pipette tip. In this way, the
researchers are able to access the intracellular surface of the membrane via the bath and
manipulate the composition that the membrane is exposed to. This technique is very

10

Image taken from axiogenesis.com
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useful when changing the environment at the intracellular domain of specific ion
channels.
The outside in patch clamp is the reverse of the inside out method and is used
when attempting to manipulate the extracellular domains of the ion channels. This
method is accomplished by slowing removing the pipette tip from the surface of the cell
membrane once a gigaohm seal is formed. If done correctly, once a small patch is
separated from the membrane, the pieces should reattach itself as a bulb at the end of the
pipette tip allowing for measurements of a single ion channel while manipulating
chemical composition of the external bath.
The cell attached patch clamp method and their derivatives are only used when
studying individual ion channels. For researchers seeking ion flux over the entire cell,
this technique would be inappropriate as it only quantifies the flux through one or a few
channels. Thus there have been variations on this method to allow for the measurement of
action potentials. While the overall theory behind the cell attached clamp remains
constant, minute changes in how the pipette tip is applied to the cell will change the
magnitude of the measurement.
The most common method for quantifying whole cell electrophysiology is
through a variation on the cell attached clamp called the whole cell patch clamp. The
main difference between these methods is the application of the pipette tip. In the whole
cell patch method, the pipette tip is applied anywhere on the cell membrane surface. A
vacuum is applied to the pipette until the cell membrane tears. The cell can then be
stimulated and the electrode is able to measure the ion flux through the entire cell.
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Figure 11: Variations on the patch clamp technique11

While traditional patch clamping methods are necessary depending on the area of
interest and cell type, there are many variations on this method that have been developed
to increase efficacy and speed of the research. One of the most recent developments in
patch clamping is the automated patch clamp which provides researchers with a much
more streamlined method of measuring electrophysiology of cells and allows
accessibility to those without prior patch clamping experience.
The automated patch clamp is a single machine that uses a vacuum to break the
cell membrane and an internal electrode to stimulate and measure electrophysiological
response. Researchers simply need to apply intracellular solution inside the chip,
extracellular solution outside of the chip along with the cell suspension. Once the vacuum
is turned on, cells in suspension will be dragged downward onto a perforated chip
fabricated with a micro-hole approximately 1-2 um in diameter. Once a single cell lands
on a hole along the chip, the seal is created and the vacuum will increase to break a tiny
section of the cell membrane. Voltage or current can then be measured across the whole
cell.
11

Image taken from microsystems.com
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Unfortunately, while this system is incredibly convenient for the average user, it
is limited in its application. This method is only valid if recording current or voltage
throughout the entire cell as the automated method is not precise enough to measure
specific ion channels on the cell surface membrane. For studies involving cellular
response to drugs or inhibitors, certain ion channels must be isolated which is only
possible using the manual patch clamping method. Additionally, this method can only be
used with cells of geometries favorable to forming a high resistive seal. Spindle shaped or
amorphous cells such as fibroblasts or neurons would likely not form a gigaseal and thus
would allow residual ions to pass between the chip and the membrane. In addition, cells
smaller than 2 um in diameter cannot be used for this method since they would be
vacuumed through the hole in the chip.

Figure 12: Microchip diagram of the automated patch clamp12

While patch clamp offers many benefits to running patch clamp experiments,
there are often many setbacks in doing so. Apart from the automated patch clamping
method, getting accurate action potential readings using traditional setups are extremely
time consuming and difficult. Since measuring any electrophysiological activity on the
12

Image taken from discoverymedicine.com
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cell requires direct contact between the cell surface and a pipette tip there are many
physical limiting factors in forming a tight seal. Cells must have an appropriate geometry
as the pipette is limited in its angle when approaching the cell. Cells that are too flat and
spread widely over the surface of the plate make it very difficult to allow for appropriate
contact with the pipette tip. Furthermore, the pipette tip must have perfect geometry, as
any imperfections would lead to piercing of the cell membrane or the inability to form a
highly resistive gigaohm seal.
In addition to dimensional problems when performing patch clamp
experimentation, there are also physical limitations when applying any stimuli to the
cells. Oftentimes it is difficult to achieve accurate action potential measurements as it
becomes more difficult and less precise to maintain a constant current throughout the cell.
Voltage gated ion channels are the limiting factor to current flow as these conduits are
only responsive to changes in voltage. Thus, with the exception of a brief charging time,
ion channels will not open in response to continuous ion flow. Therefore, cellular
recordings of action potentials are limited to a few samples before the membrane ruptures
and cellular death takes place. While voltage clamping offers superior user flexibility,
current clamping mimics the processes found in nature and thus is more applicable when
characterizing electrophysiology capacity of stem cell derived cardiomyocytes.8,9
1.3.5

Using Multi-Electrode Arrays to Characterize Cellular Electrophysiology
Multi-electrode arrays (MEAs) are geometrically fixed arrangements of electrodes

that record and monitor electrophysiological signals. The first in vitro arrays to measure
cell culture monolayers was in the 1950s to measure signals from myocytes extracted
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from chick embryos. Since then, MEAs have expanded in their form and approach and
can be applied to in vitro and in vivo studies.
The most commonly used MEAs are those for single layer cell culture
experiments. For studies that involve recording whole cell or tissue culture
electrophysiology, MEAs have become increasingly popular due to their ease of use and
practicality. The setup of a traditional in vitro MEA setup consists of four primary
components: the MEA chip, amplifier, data acquisition hardware, and data visualization
and analysis software. The MEA chip consists of a glass well that contains a grid of
electrodes that vary in spacing, size and material. Standard electrode dimensions and
quality usually consist of titanium nitride coating with diameters ranging between 10-30
microns. Additionally, inter-electrode spacing can vary between 100-500 microns.
Typically a 8 x 8 grid of 60 electrodes is most commonly used however the number of
electrodes can vary significantly depending on the application. Electrode quantity and
special dimensions are solely dependent on desired sampling rate and the quality of the
tissue. For delicate neural networks or small specimens, finer geometric tolerances are
desirable to achieve a more precise measurement. Conversely, for large-scale analysis of
a sample culture, wider intranodal spacing is appropriate.
To perform electrophysiological readings, cells must be cultured on the MEA chip
until fully mature. Once cells are visibly contracting, the MEA plate can be seated in the
amplifier to be read by the data acquisition software. The electrodes transduce the change
in voltage through the variation in ion concentration and converts into an electrical
current carried by electrons. The data acquisition software is able to record the voltage
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changes over time for each electrode and outputs the results in a grid in which each box
displays an action potential measured by the corresponding electrode on the MEA plate.
Measuring action potentials using MEAs are oftentimes the preferred method as
patch clamping is a long and arduous process that often fails to achieve meaningful
measurements if conditions are less than perfect. However one drawback with using a
basic MEA setup is that the cells must be spontaneously contractile. Since basic MEA
setups lack a stimulus that can be applied to cells, non-pacemaker cells while capable of
producing an action potential, will not be measured since there is no spontaneous flow of
ions. Advanced setups may be used to stimulate non-spontaneous cells however it can be
difficult to achieve an efficient way of stimulating myocyte like cells, thus external
stimuli are typically reserved for use in stimulating delicate neural networks.10

1.4

Pathologies of the Cardiovascular System

1.4.1

Atherosclerosis and Myocardial Infarction
Myocardial infarction or commonly referred to as a heart attack is when there is

an occlusion of the coronary arteries. These arteries supply blood to the heart itself
extending as a branch of the aorta down to apex of the heart. When the artery becomes
occluded, the heart may either develop a severe arrhythmia or extensive tissue damage
will result depending on the severity of the blockage and the period of time in which the
artery is obstructed. In almost all cases, myocardial infarction occurs in patients that have
advanced stages of atherosclerosis.
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Atherosclerosis affects upwards of 25 million people each year in the United
States contributing to a bevy of various cardiovascular diseases.11 Atherosclerosis begins
at birth and progresses throughout the human lifespan more or less aggressively
depending on a variety of different factors including diet, exercise, smoking, alcohol,
genetics, etc. Depending on the region in which atherosclerosis takes place will determine
the pathology and progression of this disease. The composition of the coronary arteries is
such that it is able to withstand high pressures due to large stroke volumes.
While atherosclerosis in the coronary arteries is one of the primary causes of heart
attacks, it doesn’t have to take place within the coronary arteries. Atherosclerotic plaques
from any vessel in the body are able to embolize within the bloodstream and flow into the
coronary arteries forming an occlusion. Additionally, any thrombus formed in the
vasculature due to cardiovascular implants are able to detach due to wall shearing
forming an embolus that could also get lodged within the coronary arteries. In most cases,
about 70% of all patients who suffer from myocardial infarction survive with a 5 year
survival rate of about 30%12. The largest factors determining the outcome of patient
survival are the time in which the patient gets treated. However patients who are unable
to receive treatment within 45 minutes, results in irreversible damage. Prolonged
ischemia results in necrosis of cardiomyocytes resulting in a significantly weaker area of
the heart. Typically the ventricles (the left ventricle being the most common) are the
regions of heart most effected due to upstream occlusion. Thus, the result of severely
damaged tissue in the ventricular areas lends itself to a variety of fatal side effects most
predominantly are mechanical problems.
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Since cardiomyocytes are a non-regenerative tissue, any damage created is
irreversible and cannot be healed in the same way a lesion would on the epidermis. In the
case of cardiomyocytes, diseased tissue becomes replaced with scar tissue, significantly
reducing functionality. Fibrous tissue is composed predominately of fibroblasts that have
a significantly lower modulus of elasticity resulting in a stiffer material compared to
muscle cells. Hence, when extensive necrosis occurs in the ventricles, healthy
cardiamyocytes secrete fibrin and collagen to replace the damaged tissue. As a result, the
ventricles are unable to contract with an even circumferential force resulting in a lower
stroke volume ejected through the systemic circuits. In addition, fibrous tissue does not
have the elasticity of healthy muscle tissue which results in dilation of the ventricle.13

Figure 13: Image of dilated ventricles post myocardial
Infarction13

Consequently, the damaged ventricle compensates for a loss of functionality and
thus cardiomyocytes will hypertrophy in response to an increased load. If not corrected,
cardiomyocytes will continue to hypertrophy until the entire heart becomes swollen
leading to further mechanical problems. Thus to prevent this chain of pathological events
13
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from occurring, it is critical to implement treatments that reduce the stresses on the heart
and ultimately find a solution to replace diseased tissue with healthy functioning
cardiomyocytes.
1.4.2

Pathologies of the Cardiac Conduction System
Cardiac arrhythmias are one of the most common cardiovascular pathologies

globally that affects over 14 million people a year in the United States alone. There are
many different varieties of arrhythmias which is used as an umbrella term for any subset
of conditions in which the heart beats too fast or slow. Arrhythmias are typically
measured and diagnosed using an electrocardiogram (EKG or ECG). The contraction of
the heart is visualized using a waveform in which is subdivided into four sections each
corresponding to a unique event in the cardiac cycle. An example of an EKG of a healthy
person is shown in figure 14. The p-wave corresponds to the atrial contraction and is
shortly followed by the QRS complex representing ventricular depolarization and
contraction while the T wave represents ventricular repolarization. The PR interval
indicates the transit time between the SA and AV node and similarly the QT interval
indicates the time for the ventricles to contract and relax. Arrhythmias can be quickly
diagnosed by visualizing an abnormal waveform and will vary depending on the type of
arrhythmia.14

28

Figure 14: Normal EKG diagram displaying peaks
and intervals14

There are four main types of arrhythmias: premature atrial and ventricular
contraction, supraventricular tachycardias, ventricular arrhythmias, and bradyarrythmias.
Premature atrial and ventricular contractions occur when another region of the atria or
ventricle contracts before the SA/AV node. This triggers a premature heartbeat that
occurs in healthy individuals of all ages and does not necessarily indicate a predisposition
to a heart condition. They are typically perceived as a feeling a skip in heartbeat or a
pause between heartbeats and are the most prevalent type of arrhythmia. No medical
treatment is necessary unless irregular beating continues.
Bradyarrhythmias are the opposite of tachycardia arrhythmias in that they are
conditions in where the heart rate is slower than the normal resting rate of 60 beats per
minute. This condition is caused from a number of variables ranging from lifestyle to
nodal irregularities. Commonly, the cause results from impairment in the ability of signal
propagation to occur from one of the nodes. Oftentimes athletes have resting bradycardia
due to high training intervals where the heart is being over exerted. Bradycardia

14
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oftentimes goes untreated especially if the resting heart rate doesn’t drop below 50 beats
per minute and is not considered a life threatening condition.
Supraventricular tachycardia (SVT) is an arrhythmia occurring when typically the
SA node sends signals sporadically and at varying time intervals. Common conditions
such as atrial flutter and fibrillation are all categorized as SVTs. It manifests itself in an
accelerated heart rate and many irregular signals are blocked at the AV node which can
be viewed as an increased peak of the P wave as shown in figure 15. Fortunately this is a
less serious condition as the AV node acts as a safeguard allowing only a small fraction
of these misfires to pass. Thus normal contraction of the ventricles allows for a proper
ejection of blood and is not life threatening if diagnosed and treated at onset.

Figure 15: EKG of a patient with supraventricular
tachycardia15

Ventricular arrhythmias are less common but can be lethal if not treated
immediately. This is caused by premature contractions of the ventricles due to other
regions firing independently of the AV node. This condition is the most obvious
abnormality on an EKG and has a varying waveform with broad QRS complexes as

15
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shown in figure 16. Patients often experience chest pain, rapid heartbeat and dizziness or
nausea.15

Figure 16: EKG of a patient with ventricular tachycardia16

1.4.3

Current Treatment Options for Patients with Heart Disease
There are a number of options available for patients who suffer from myocardial

infarction. Depending on the extent of the tissue damage and the age of the patient among
other factors will determine the course of treatment. One of the most common procedures
performed in patients who are known to have advanced atherosclerosis is a coronary
artery bypass graft (CABG). CABG is a procedure where a section of healthy artery or
vein is removed somewhere from the body (mammary artery/saphenous vein) and is
stitched from the aorta, or a branch of the aorta, past the occluded region in the coronary
artery (referenced in figure 17)
Depending on the extent of plaque buildup in the coronary arteries will determine
whether multiple grafts will have to be made during surgery. One shortcoming with this
procedure is finding veins or arteries suitable for grafting. Oftentimes, if atherosclerosis
has advanced significantly where the patient needs multiple CABG’s the accumulation of
plaque is also found in the vessels desirable for this grafting procedure. Thus, CABG may
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not be an option for patients with very progressive atherosclerosis. In addition, this
treatment does nothing to address the problem of restoring functional properties of
cardiac muscle tissue to the scarred areas of the ventricles post MI. While this course of
treatment is successful in preventing future MI’s, it doesn’t address the damage that has
already been done.

Figure 17: Diagram of a CABG procedure17

CABG patients are still as risk for a number of mechanical failures. As detailed
previously, scarred regions of the heart are significantly weaker than cardiac muscle
tissue and as a result of being exposed to extreme pressures of the ventricle, patients are
at risk for ventricular aneurysm. To prevent this from happening, surgeons will often
perform an endoventricular circular patch plasty (EVCPP) concurrently with a CABG
procedure. This procedure entails making an incision down the scarred region of the
ventricle, stiches are sewn around the infarct area and finally the stiches are pulled
together closing the ventricle. This eliminates the risk of an aneurysm or rupture of the
ventricular wall, thus reducing the dilation of the left ventricle. In addition this procedure
is also shown to have improved left ventricular ejection compared to CABG alone.

17
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Unfortunately, this treatment has not shown to significantly improve mortality rates in
patients.16
Another course of treatment that is common for patients post MI is a left
ventricular assist device (LVAD) (Figure 18). This device is a pump connected to two
tubes that suture from the left ventricle to the aorta. This device addresses the mechanical
deficiencies of the heart post MI however this course of treatment is not without its
shortcomings. While LVADs significantly alleviate stresses on the ventricle, patients
must remain on anticoagulants for the rest of their life to reduce the risk of rejection22.
Additionally, up until recently, older models of this device were large and bulky and
required the patient to wear a backpack housing the external battery to the device.
Current models emerging on the market now are significantly smaller and can be charged
externally so as not to have any wires protruding from the body to power the LVAD.
Furthermore, the impeller inside the pump is prone to expose blood cells to excess
shearing causing the patient to essentially lose healthy blood cells. Improvements in the
impeller design are currently in development to reduce turbulent flow of the blood cells
contacting impeller edges thereby reducing cell shear.17

Figure 18: LVAD implantation and technical diagram
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illustrating components and device placement18

For patients with arrhythmias, there are a number of treatment options depending
on the type of arrhythmia. For patients with less serious arrhythmias originating above
the AV node simple physical maneuvers have been found to be successful in blocking
conduction thorugh the AV node by increasing parasympathetic nervous supply to the
heart via the Vagus nerve. Vagal maneuvers include gagging, holding ones breath or
coughing to slow the heart rate.
When physical maneuvers are insufficient in reducing heart rhythm, drugs may
become necessary. Some drugs prevent arrhythmias by interfering with sodium and
potassium gated ion channels while others function by acting as anti-parasympathetic
nervous system agents. There are many drugs on the market that are very specific
depending on the subset of arrhythmia the patient is diagnosed with. They are generally
very successful as a prolonged treatment option and are implemented whenever possible
as it’s non-invasive and has good patient outcome.
For patients with life threatening arrhythmias that cannot be sufficiently treated
using the discussed options, more drastic and invasive measures must occur. Patients who
have ventricular fibrillation leading to cardiac arrest require defibrillation. Defibrillation
consists of providing a high dose of current directly to the heart. By administering a high
external current, the cardiac conduction system can reset and return to normal sinus
rhythm. Defibrillators come in many varieties and can be external or implantable.
Automated External Defibrillators (AEDs) are most common and can be used by the
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layperson and can be found in public access places. AEDs involve attaching electrode
pads to the patients chest and pressing a button to deliver a high voltage shock to the
patient. This may be repeated numerous times as necessary and is found to significantly
increase survival rates with cardiac arrest patients surviving close to 40% of the time as
opposed to 0% with no defibrillation. Additionally, implantable defibrillators are
common in patients with a medical history of ventricular fibrillation as these implants can
detect the fibrillations and signal an immediate impulse to the heart.18
Similar to defibrillators, the most common implantable device for correcting
arrhythmias are pacemakers. These are commonly used for patients with bradycardia
where recovery is unexpected or for patients recovering from MI. Modern pacemakers
are programmable and allow the cardiologist to tailor the settings to the patients
condition. Pacemakers can either be singular or biventricular and can monitor and
provide pacing for both atrial and ventricular arrhythmias which are common in heart
failure patients. They comprise of three components: a pulse generator, leads and
electrodes on the end of each lead. The pulse generator is implanted below the collarbone
and the leads are snaked through a large vein to the interior of the heart where they rest
on the heart wall. The electrodes can monitor the beating and provide a signal if any
abnormalities are detected.19 A modern defibrillator and positioning can be viewed in
figure 19.
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Figure 19: Diagram of pacemaker with placement
of biventricular leads19

1.5

Cardiac Tissue Engineering and Regenerative Medicine

1.5.1

Approaches to Cardiovascular Regenerative Medicine
There are two current methodologies that are under investigation for restoring

functional myocardium in a clinical setting. The first is by administering cellular signals
and growth factors to stimulate the differentiation of recently discovered stem cells
residing in heart tissue. The second and more understood approach is regeneration of
cardiomyocytes through stem cell differentiation. Various protocols have been developed
for in vivo and in vitro clinical applications using a variety of different stem cells yet
current methodologies all possess major barriers to becoming clinically successful.
The most attractive approach to replacing myocardial scar tissue is through
intravenous delivery of stem cells to the target site which has shown to regenerate
myocardium and restore function in animal models. Using an in vivo model is attractive
for a multitude of reasons. From a clinical perspective, the procedure is minimally
19

Image taken from mayoclinic.org
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invasive and would ideally require a series of intravenous injections. From a research
perspective, in vivo studies provide global and regional cardiac performance benchmarks
that would otherwise be impossible to quantify through in vitro studies. However, there
are many significant drawbacks to in vivo studies when characterizing cell physiology.
Current techniques for homing cells to the target site remain largely ineffective with
many studies showing cell retention rates of less than 10%.20 In addition, once stem cells
are incorporated into native tissue it becomes impossible to characterize cell
differentiation on a microscopic level and thus can only gross evaluations can be made.
Furthermore, the cost and time to perform in vivo experimentation is often exceedingly
inconvenient and impractical for many laboratories. Thus, in vitro experimentation is
necessary and will be the focus for the remainder of this paper.
In vitro expansion of cells and differentiation through chemical and physical
stimuli remain the predominant protocol for stem cell differentiation today. Cell culture
provides greater control and handling of specimens. Additionally, gene expression of
specific markers can be imaged and quantified. Electrical activity can be measured in
individual cells or in spatially arranged multi-dimensional tissue structures. Cell culture is
typically expanded on the order of 107-109 cells for seeding onto tissue scaffolds. Many
studies over the past decade have been devoted to creating a tissue-engineered construct
for myocardial infarct tissue replacement. There have been many challenges to date with
developing an FDA approved myocardial construct including, cell density, cell seeding,
and electrical viability among others.21
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While differentiating cardiomyocytes have been effectively demonstrated in many
stem cell lineages, many have limiting factors with current methodologies that make it
difficult to be viable for use in a clinical approach. Various stem cells have a unique set
of advantages and drawbacks when considering their ability to differentiate into
cardiomyocytes and their availability using current harvesting and culturing techniques.

1.5.2

Embryonic Stem Cells in Cardiac Tissue Engineering
Embryonic stem cells are pluripotent cells that are derived from the inner cell

mass of the blastocyst. Human embryos take approximately four to five days after
fertilization to develop into the blastocyst consisting of between 50-150 cells. At this
stage, the embryo can be sacrificed to harvest the inner cell mass for cell culture. Many
studies including He at el have shown to differentiate embryonic stem cells into
ventricular, atrial, nodal and purkinje-like cells making embryonic stem cells the most
highly desirable cell type for cardiomyocyte differentiation studies. The ability to
differentiate into any primary germ layer is the primary distinction between embryonic
and adult stem cells.
Embryonic stem cells possess the ability to propagate indefinitely in an
undifferentiated state when provided the proper conditions and signals. Providing the
proper growth factors, and cell signaling molecules, differentiation can be tailored to
desired cell type. During early development, cells are small and spherical lacking
myofibrils and are irregular in spatial arrangement. As maturation continues, the cells
become elongated expressing well developed sarcomeres and myofibrils. Singular cells
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will spontaneously beat within a week and a functional syncyctium will appear in culture
once cellular junctions are fully developed. Additionally, electrophysiology can be
measured at early developmental stages. Studies have shown ion channel development
and measurable action potential readings before spontaneous beating occurs in culture
flasks.22,23
Zhu et al published a study in 2015 measuring the variability of over 23,000
action potentials in embryonic derived cardiomyocytes and found that action potentials
could be measured as early as 10 days.24 Furthermore they found between multiple
subpopulations of cardiomyocytes within each culture displaying differences in peak to
peak intervals between action potentials suggesting that variability in culture conditions
may effect electrophysiology between cells of the same population. However, compared
to other stem cell types embryonic stem cells have the least variability when compared to
induced-pluripotent or adipose derived stem cells. This is largely due to the fact that
differentiation of embryonic derived cardiomyocytes has been largely standardized
compared to other stem cell lineages.25,26
Although the robust and distinguished potential of embryonic stem cell
differentiation is the most desirable when culturing and expanding cardiomyocytes, there
are many drawbacks in the use of these cells. There are many ethical and moral concerns
using this cell type as the embryo must be sacrificed in order to harvest the inner cell
mass. Federal and state level funding has historically been restricted in laboratories
attempting to use embryonic stem cells studies. Therefore, there has been much work in
the scientific community during the beginning of the 21st century to develop a cell line

39

that was pluripotent, yet didn’t require the sacrifice of human embryos. In 2006 a
laboratory in Japan developed the first pluripotent stem cell derived from a human
fibroblast which they named induced pluripotent stem cells or iPSCs
1.5.3

Induced Pluripotent Stem Cells in Cardiac Tissue Engineering
Induced pluripotent stem cells (iPSC’s) is the ideal cell type from a regenerative

medicine standpoint. They have been shown to be pluripotent and can be derived from
many different adult cell types. In order to induce pluripotency in a mature cell,
introduction of four specific transcription factors must be introduced into the cell. In 2006
Yamanaka et al showed these factors to be Sox2, Oct4, cMyc and Klf4 which were later
named Yamanaka factors.27 Upon introduction of these transcription factors in a fully
mature adult cell, the cell reverts back to a pluripotent or undifferentiated state that can
then be re-differentiated into the desire cell type. Furthermore, these cells have been
shown to proliferate indefinitely while in an undifferentiated state making them more
attractive as a source for cardiomyocyte regeneration or other cell types under which
undergo cell cycle arrest where proliferation is terminated in adults.28

Figure 20: Reprogramming an adult cell to a pluripotent state20

20

Image taken from mdstate.com

40

Currently the biggest setback in reprogramming cells to pluripotency is the
efficiency using current methods. The rate at which Yamanaka’s laboratory was able to
convert fibroblasts to a pluripotent state was estimated between 0.01-0.1% of mature
fibroblasts used in the study. While efficiency rates have increased since, the initial study,
conversion rates are still too low to be considered for anything other than small clinical
and laboratory studies.
Differentiation studies have shown iPSCs to have a very high cardiomyocyte
development potential. However due to the broad range of methods used to induce
pluripotency combined with variance in cell source and maintenance consistency, iPSCs
have shown to have high phenotypic variability making some differentiation protocols
highly efficient while others completely unsuccessful.29 Zhang et al compared the yield
and colony populations between ESC derived cardiomyocytes and iPSC derived
cardiomyocytes and found ESC-derived cardiomyocytes to have a higher percentage of
spontaneously beating cells as well as having a faster beat frequency. The study also
showed residual expression of pluipotency genes in fully developed iPSC derived
cardiomyocytes.30 Du et al showed that action potential morphology in iPSC derived
cardiomyocyte culture is dependent on cell seeding density further suggesting variability
amongst studies with different seeding densities.31
As evidenced, the biggest problem with deriving cardiomyocytes using induced
pluripotent methods is variability in the somatic cell type used as well as the
differentiation methods. Lian et al showed that Wnt/B-catenin signaling through GSK-3
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inhibition and suppression following mesoderm formation yielded 82-95%
cardiomyocyte purity in 2D culture.32
Induced pluripotent stems cells have been shown to be electrically viable
mimicking the development cycle and action potentials found in ESC derived
cardiomyocytes. Action potentials of ventricular and pacemaker cells have been shown to
replicate native cardiomyocyte tissues. Spontaneously beating cardiomyocytes can be
observed in culture flasks as early as 10 days followed by a fully beating synctytium
weeks later.33
Once standardized protocols and sourcing become more prevalent, iPSCs possess
unique potential in becoming a clinically viable solution to many diseases. Unfortunately
one of the largest remaining challenges is the time and resource expense to produce a
high enough yield to be used in tissue engineering applications. Current studies have
revealed new methods of significantly higher efficiency rates in reprogramming adult
cells, however these protocols have been flagged as safety hazards for future clinical
studies. Researchers at the University of Wisconsin have found that by deleting the tumor
suppressant gene p53, adult cells have been shown to significantly increase
reprogramming rates. These cells when expanded in culture have been shown to
propagate at significantly increased rates that mimic cancerous cell growth. Thus a
tradeoff currently exists between safety and efficiency which must be considered when
evaluating the potential for iPSC use in regenerative medicine applications.34
While iPSCs are under heavy investigation for future clinical applications
especially for the development of non regerative tissues, the logistics of using iPSCs to
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develop entire organs or pieces of tissue remains a enormous challenge. The time
required to reprogram and expand the number of cells necessary to create a tissue
engineered construct would require huge monetary costs as well as critical time that the
patient may not have. Thus using easily harvested and abundant adult cells is increasingly
attractive when determining candidates for cellular therapy. Researchers have turned to
mesenchymal stem cells as a source for cellular therapies for many different treatments in
clinical applications. While these cells lack pluripotency, researchers have been
investigating their potential for the use of cardiac tissue engineering applications.
1.5.4

Mesenchymal and Adipose-Derived Stem Cells in Cardiac Tissue
Engineering
Adipose derived stem cells (ASC’s) are mesenchymal stem cells (MSC’s) that can

be found and isolated from adipose tissue. MSC’s are multipotent stromal cells that have
the ability to differentiate into a variety, but limited, number of cell types35. MSC’s have
commonly been known to differentiate into functional chondrocytes, osteocytes,
adipocytes and myocytes. MSC’s are derived from the mesoderm and were originally
found present in bone marrow. Researchers have now found MSC’s to be present in a
variety of different tissues including adipose tissue. In fact, MSC’s are found to be 500
times more concentrated per gram of adipose tissue than per gram of bone marrow36.
Morphological characteristics of MSC’s include a small cell body with fibroblast like
characteristics containing a prominent nucleus. Small amounts of Golgi apparatus,
Endoplasmic reticulum, and mitochrondria can be found as well.

43

Interest in MSC therapy has increased significantly throughout the scientific
community for a variety of reasons. For starters, MSC’s are abundant in adult adipose
tissue and are easily extracted. Large quantities of ASC’s are easily extracted through a
single procedure without the need for cell culture expansion37. Furthermore, the benefit of
using ASC’s in a clinical setting is two-fold. First, cells can be harvested non-invasively
compared to bone marrow extraction or other MSC population dense organs. Secondly,
cells can be harvested from an autologous source thereby eliminating any
immunogenicity shortcomings. In the interest of generating functional cardiomyocytes,
ASC’s are found to have the ability to differentiate into a variety of functional cell
lineages, including myocytes. Furthermore, ASC’s have been well documented to induce
angiogenesis as well as containing anti-inflammatory properties.38
Methods for inducing differentiation in ASC’s has been widely researched and
well documented for certain cell types. As stated previously, ASC’s have been known to
differentiate into chondrocytes, osteocytes and adipocytes with relatively little ease. This
could be due to the fact that these cells are static cell types in which are functionally
intended to support forces, store energy, or maintain shape of a body. In the case of
myoblasts and more specifically cardiomyocytes, the function of these cells is more
involved and thus differentiating into these cell lines is a more complex procedure and
one that is difficult to reproduce in the laboratory with positive results.39
In 2004 Planat-Benard was one of the first laboratories to produce spontaneous
beating cardiomyocytes from adipose tissue stromal cells in adult mice. They cultured the
cells in methylcellulose culture medium along with a cocktail of supplements including
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fetal bovine serum and 2-mercaptoethanol. Electrophysiological activity was measured
using current clamp on a whole cell patch configuration. The adipose derived
cardiomyocytes exhibited spontaneous electrical activity between -40 and -60 mV with
62 millisecond intervals. The action potentials measured strongly resembled pacemaker
cells lacking a stage two or three region in the graph. Furthermore, immunostaining
indicated presence of alpha actinin, beta myosin heavy chain, and connexin 43 which are
all indicative of cardiomyocyte formation.40
Since this journal was published, many other scientific research groups have tried
to replicate the protocol or produce different protocols to achieve the same results. Choi
et el reviewed many protocols involving the differentiation of ASCs using a modified
cardiogenic media, 5-azacytidine, and trichostatin A. They also attempted to co-culture
ASCs with rat cardiomyocytes and found the differentiated cells to possess many
cardiomyocyte markers. However, spontaneous contraction was never achieved even
after eight weeks of culture. Many other studies have shown that cultured and freshly
isolated ASCs are capable of improving functional cardiac output when directly injected
into the heart suggesting that these cells are capable of differentiating into fully
functional cardiomyocytes. However, it remains unclear if ASCs are able to differentiate
into pacemaker cells as many other studies have attempted to reproduce the PlanatBernard study unsuccessfully.41
Although ASCs lacks the pluripotency of other stem cells, they have great
potential in cardiac tissue engineering. The ability to harvest these cells so quickly and
easily makes for an excellent patient driven source for treatment. While there is still
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much work ahead in establishing a standard protocol for isolation and culture of ASCs to
achieve maximum cardiomyocyte yield, if perfected may be the most optimal cell for use
in clinical setting.
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Chapter 2: Project Aims and Rationale
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Current treatment options for patients with varying heart ailments serve as a
bridge to prevent further complications. There are currently no tissue engineered clinical
solutions available to promote growth and regeneration of functional myocardium. Thus,
there are deficiencies in current clinical treatments that need to be addressed through
translational tissue engineering approaches. Various stem cell therapies are being
explored and used in phase 1 clincal trials yet there are many drawbacks specific to the
type of stem cell being used. While many studies have been able to successfully generate
ventricular cardiomyocytes, far less have been able to generate high volumes of
pacemaker cells that are critical in providing clinical treatments for patients with
arrhythmias. This research was driven to provide further insight into cellular
electrophysiology to the tissue engineering community through the following aims:

1. Measuring electrophysiology of induced-pluripotent, embryonic and adipose
derived stem cells using various patch clamping techniques and multielectrode
arrays.
2. Determining the electrophysiological viability of adipose derived stem cells cocultured with differentiated embryonic derived cardiomyocytes.
3. Investigating the potential to generate pacemaker cells from adipose derived stem
cells using 3D scaffolds.
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Chapter 3: Materials and Methods
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3.1

Cell Culture Techniques

3.1.1

Culturing the iCell® induced-pluripotent stem cells
Preparation of a 0.1% gelatin solution was made dissolving 100 mg of gelatin in

100 ml of water in a sterile bottle. Sterilzation of the solution was performed by
autoclaving the solution using the liquid cycle setting.
Addition of 2 mL of gel solution was added to two 6-well plates and were
incubated in 37°C for 1 hour cells were placed in a 37°C water bath for 4 minutes to
thaw. The cell vial was dried and then sprayed with 70% ethanol and placed in a
biosafety cabinet. The contents of the vial were then transferred to a sterile 50 mL
centrifuge tube using a 1 mL pipette, rinsing the vial with an additional 1 mL of iCell®
Plating Media to completely remove all cells. The media was then added dropwise to the
50 ml centrifuge tube over the course of 90 seconds to minimize osmotic shock. Then 8
mL of plating media was added to the centrifuge tube with the first mL added drop-wise
for the first 60 seconds and then the remaining 7 ml over the next 30 seconds. The
contents of the centrifuge tube were gently mixed by inversion 3 times before counting
the cells using a cell scepter. The cell viability was measured at 1.2*106 cells per mL and
were plated at 200,000 cells per well. Cells were incubated overnight and after 24 hours
the plating media was exchanged with 2 mL per well of fresh iCell® Maintenance Media.
Media was changed every other day until cells fully matured.
3.1.2

Culturing the Cytiva™ embryonic stem cell derived cardiomyocytes in 2D
Preparation of RPMI/B27™ medium for culture was prepared using 500 mL of

RPMI+Glutamine medium as well as 10 mL of the B27™ supplement distributed by
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General Electric Health. The B27™ supplement was thawed in a 37°C water bath. Upon
removal, it was transferred to a biosafety cabinet along with the RPMI media to be
combined and vacuum filtered for complete sterilization. In addition, 6 well plates were
pretreated with a 1 mg per mL fibronectin solution for 2 hours at 37°C.
Cells were thawed in a 37°C water bath with gentle agitation until ice crystals
disappeared in the vial. Cells were immediately transferred to a 50 mL tube in the
biosafety cabinet and an additional 1 mL of room temperature RPMI was added to the
cryovial and then transferred dropwise to the cell suspension with gentle mixing. Over
the course of 2 minutes, 8 additional mL of RPMI media was added to the tube to prevent
osmotic shock. The cell suspension was then centrifuged at 300 g for 5 minutes at 20°C.
The supernatant was removed using an aspirator and the cells were re-suspended in 6 mL
of media. One mL of the suspension was added to each well of the pretreated 6-well
plate. The media was changed daily and the cells were incubated at 37°C for a week
before being used in patch clamp studies.
3.1.3

Culturing ADSCs in a Monolayer (2D)
The media was assembled using 500 mL of mesenPRO RS™ basal medium and

10 mL of mesenPRO RS™ growth supplement distributed by ThermoFisher Scientific.
The supplement was thawed in a 37°C water bath and transferred to the biosafety cabinet
with the medium to be mixed and vacuum filtered. The container containing mixed media
was immediately wrapped with aluminum foil as the supplement is light sensitive.
To plate the cells, 30 mL of fresh media was transferred to a 50 mL conical tube,
wrapped with aluminum foil and warmed to room temperature. One vial of Invitrogen
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ADSCs concentrated at 4*106 cells per mL were thawed in a 37°C water bath for 3
minutes until ice crystals fully melted. The cells were then transferred to a 15 mL conical
tube and 1 mL of media was used to rinse the contents of the cryovial. Four mL of media
was added slowly to the tube and centrifuged down at 300 g for 5 minutes. The
supernatant was aspirated and the cells were re-suspended in 1 mL of media. In a Corning
T-175 culture flask, 20 mL of fresh media was added along with the 1 mL of cell
suspension. Media was changed every 48 hours and the cells were passaged once
confluent.
For cell passaging, 6 mL of a 0.1% Gibco® trypsin-EDTA solution along with 60
mL of fresh media was warmed in a 37°C water bath. The media from the culture flask
was aspirated and rinsed with 20 mL of room temperature sterile PBS solution. After the
cells were rinsed, 6 mL of the trypsin-EDTA solution was added to the culture flask and
incubated at 37°C for 5 minutes. Once the cells were inspected under the microscope to
confirm detachment, 12 mL of media was added to the flask to deactivate the trypsin. The
cell suspension was pipetted 3 times to thoroughly rinse the bottom of the flask. The 18
mL suspension was then transferred to a 50 mL tube and centrifuged at 300 g for 5
minutes. The supernatant was aspirated and re-suspended in 6 mL of media. Two mL of
cell suspension were then added to 3 T-175 flasks with 18 mL of media. The flasks were
incubated at 37°C and the media changed every 48 hours.
3.1.4

Culturing ADSCs in 3D spheroids
To make the scaffolds, a 1% gelatin solution was made by added 1 gram of

agarose to 100 mL of water in a beaker. The solution was heated in a microwave until
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boiling stopping to swirl the solution every 10 seconds. Once the gelatin had completely
dissolved, the solution was placed on a hot plate set to 70°C with a stir bar for continual
agitation under a biosafety hood.
A bucket filled with ice was placed in the hood upon which a Sigma-Aldrich 1236TO 3D Petri Dish® mold was placed. To form the gels, 500 uL of agarose gel solution
was then pipetted into the mold and hardened over the course of three minutes. To
remove the cast from the mold, the ends were pinched on either side and inverted above a
clean petri dish. The gels were then placed separately in a 12 well plate and equilibrated
with cell culture medium for 15 minutes at 37°C. This process was repeated twice to
completely equilibrate the gel with the cell culture media. The media was then aspirated
and the ADSCs were seeded in the cell seeding chamber at a density of 1.08*106 cells per
gel for a final concentration of 30000 cells per sphere. The gels were incubated for 30
minutes to allow cells to completely settle before adding 1 mL of culture media to each
well. Cells incubated in the gels for 1 week before removal with fresh media changes
every day.

3.2

Patch Clamping Techniques

3.2.1

Automated Patch Clamp Setup
First the media was aspirated in each well that was to be used and rinsed with

PBS twice. One mL of Sigma-Aldrich Accutase® cell detachment solution was added to
each well and then incubated for 5 minutes at 37°C. Once cells were observed under the
microscope to confirm that they have been lifted, an equal amount of media (~1 mL) was
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then added to the wells to deactivate solution. The cells were then added to a 15 ml
conical tube and were centrifuged at 1000 rpm for 3 minutes. The supernatant was
aspirated and the pellet was re-suspended in 1 mL of fresh media.
For this experiment, the Nanion Port-a-Patch® automated patch clamp setup was
used and 5 mL of intracellular, extracellular and seal enhancer solutions were prepared
beforehand shown in table 1:
Internal Solutions

External Solutions

Seal Enhancer

50 mM KCl

140 mM NaCl

80 mM NaCl

10 mM NaCl

4 mM KCl

3 mM KCl

60 mM K-Flouride

1 mM MgCl2

10 mM MgCl2

20 mM EGTA

2 mM CaCl2

35 mM CaCl2

10 mM Hepes

5 mM D-glucose

10 mM Hepes

monohydrate
285 mOsmol, pH 7.2

10 mM Hepes

285 mOsmol pH 7.2

298 mOsmol, pH 7.2
Table 1: Extracellular, intracellular and sealant compositions

The appropriate Nanion Port-a-Patch® setup is as follows and can be viewed in
figure 21. The Port-a-Patch® is first connected via a small diameter tube to Nanion’s
Suction Control Pro® vacuum system. In addition the Port-a-Patch® is connected to the
HEKA EPC Patch Clamp Amplifier which is connected to a computer. For these
experiments the HEKA PATCHMASTER data acquisition software was used in
conjunction with this setup. For all patch clamp studies using the Nanion automated
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system, NPC®-1 chips were used which contain a borosilicate glass slide with varying
micron sized apertures. For the majority of the experiments, the 5 MOhm chips were used
as the size of the iPSCs and ESCs most appropriately suited the chip diameter.

Figure 21: Nanion Port-a-Patch Setup

3.2.2 Suspending the Cells onto the Microchip
Cells were suspended onto the chip using the prepared solutions as follows. First,
5 uL of intracellular solution was placed on the inside well of the microchip. The top
plate of the Port-a-Patch is removed and the chip is screwed into place accordingly as
illustrated in figure 22. The cap was replaced and 5 uL of extracellular fluid was pipetted
on top of the microchip being sure that the extracellular lead contacts the fluid. The
vacuum is then applied to exert positive pressure on the solution to prevent
contamination. Five microliters of cell suspension is then immediately and forcefully
pipetted to the extracellular solutions to provide a downward force by which the cells will
gravitate to the bottom of the chip. Once a cell comes into contact with a hole on the chip,
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the resistance will increase between the cell membrane and the chip. Upon seeing a spike
in the resistance value outputted by the software, 15 uL of enhancer solution is added
until a tight seal forms between the cell and the chip. The seal enhancer is replaced with
extracellular fluid following a gigaohm seal and the vacuum is increased incrementally
until the cell membrane is compromised. Upon rupturing the cell membrane, current
clamp and voltage clamping experiments were performed for each cell type.

Figure 22: Microchip setting and placement

3.2.3

Experimental Parameters for Electrophysiology Studies
To perform voltage or current clamp experiments, the cell must be stimulated

with either current or voltage above the membrane potential. The tables below list all
essential parameters that were input into the Patch Master software for each
corresponding study.
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Configuration	
  
Input	
  
Voltage/Current	
  
Increments	
  
Number	
  of	
  Sweeps	
  
Sample	
  Interval	
  
Sweep	
  Interval	
  

Sample	
  1	
  
Voltage	
  
Clamp	
  

iCell	
  iPSC	
  Study	
  
Sample	
  2	
  
Current	
  
Clamp	
  

-‐140	
  mV	
  
10	
  mV	
  
20	
  
200	
  us	
  
5	
  s	
  

-‐40	
  mA	
  
15	
  mA	
  
4	
  
200	
  us	
  
15	
  s	
  

Sample	
  3	
  
Current	
  
Clamp	
  

Sample	
  4	
  
Current	
  
Clamp	
  

-‐40	
  mA	
  
15	
  mA	
  
4	
  
200	
  us	
  
15	
  s	
  

10	
  mA	
  
15	
  mA	
  
4	
  
200	
  us	
  
15	
  s	
  

Table 2 iPSC study input parameters

Configuration	
  
Input	
  
Voltage/Current	
  
Increments	
  
Number	
  of	
  Sweeps	
  
Sample	
  Interval	
  
Sweep	
  Interval	
  

Cytiva®	
  ESCs	
  Study	
  
Sample	
  1	
  
Sample	
  2	
  
Current	
  
Current	
  
Clamp	
  
Clamp	
  

Sample	
  3	
  
Current	
  
Clamp	
  

Sample	
  4	
  
Current	
  
Clamp	
  

-‐45	
  mA	
  
15	
  mA	
  
4	
  
200	
  us	
  
15	
  s	
  

-‐60	
  mA	
  
15	
  mA	
  
4	
  
200	
  us	
  
15	
  s	
  

-‐90	
  mA	
  
15	
  mA	
  
4	
  
200	
  us	
  
15	
  s	
  

-‐45	
  mA	
  
15	
  mA	
  
4	
  
200	
  us	
  
15	
  s	
  

Table 3: ESC study input parameters

ESC-‐ADSC	
  Co-‐Culture	
  Study	
  
Sample	
  1	
  
Configuration	
  
Current	
  Clamp	
  
Input	
  Voltage/Current	
  
-‐45	
  mA	
  
Increments	
  
15	
  mA	
  
Number	
  of	
  Sweeps	
  
8	
  
Sample	
  Interval	
  
200	
  us	
  
Sweep	
  Interval	
  
15	
  s	
  
Table 4: ADSC co-culture study parameters
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3.3

Multielectrode Array Techniques
For this study, model Multichannel systems 60MEA200/30iR-ITO chips were

used along with a Multichannel systems MEA 1060 Amplifier and Data Acquisition
Module. Cytiva® MEAs were autoclaved at 110°C for 30 minutes and ESCs were
thawed as described in section 3.1.2 and plated in 2 MEAs treated with fibronectin at
200,000 cells per MEA. The cells were incubated over the course of a week changing the
media once every 24-hours. Once cells were observed spontaneously contracting the
MEAs were recorded for electrophysiological readings. To read the MEAs they are set
within the amplifier matching the ground electrode on the plate to the grounded pin on
the amplifier. The MEA is then firmly mounted into place by pressing the top half of the
amplifier down into the pins on the bottom half of the amplifier. The amplifier is then set
within a metal cage to prevent signal noise during recording. The plates were sampled at
5 kHz and still frame and full motion videos of electrophysiological activity were taken.
3.4

Differentiation Methods of ADSCs

3.4.1

Differentiation of ADSCs in 2D Co-Culture
ADSCs and ESCs were cultured as described in sections 3.1.2 and 3.1.3

respectively. A 12-well plate was divided into 3 groups of 4 samples each, the groups are
as follows: ADSC, ESC and ADSC-ESC co-culture. The ADSC group was seeded at a
density of 200,000 cells per well, the ESC group was seeded at 200,000 cells per well and
the co-culture group was seeded at a 1:2 ratio (60,000 ESCs per well to 120,000 ADSCs
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per well). The cells were incubated at 37°C for one week before performing patch clamp
recording. The parameters used for this study are shown in table 4.
3.4.2

Differentiation of ADSCs in 3D Spheroids
ADSCs were cultured and seeded in agarose gels as described in section 3.1.4.

Cells were incubated undisturbed in the scaffolds for 48 hours after which the cells were
removed. Removal of the spheres required inverting each gel and gently tapping the side
of the 6-well plate to loosen the cells from the wells. Then, each scaffold was rinsed
repeatedly with PBS to completely dislodge the cells from the molds. Once all the
spheroids were removed from the wells, the gels were discarded and the spheroids were
transferred evenly in four collagen type 1 coated Flexcell BioFlex® culture plates. These
are specialized plates that contain rubber surface membranes for delivered mechanical
load regimens to the cell culture. Each plate corresponds to a different method of
differentiation as follows: Mechanical stimuli, chemical stimuli, mechanical and
chemical stimuli, as well as a non-stimulus control group. All groups were differentiated
in RPMI+Glutamine media with 10% Bovine growth serum and 1% antibiotic. Chemical
differentiation groups were additionally treated using 5-Azocytidine at a concentration of
10 uM/well for 24 hours.
3.5

Flexcell® Bioreactor Experimental Setup and Software Configuration
Mechanical stimuli was administered using the Flexcell FX-5000™ Tension

system. The system held the culture plates into place using the BioFlex® Loading
Stations™ with 25 mm loading posts as pictured in figure 23.
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Figure 23: Flexcell culture plates mounted in the loading station

To position the plates, a petroleum jelly is swabbed along the interior of baseplate
rim and the plates are pressed into the depression. The Bioflex® Baseplates were placed
at the bottom and top of the loading station and mounted into place using screws. The
baseplate is then connected via vacuum tubing to the FX5K™ Tension FlexLink® a
remote tension or compression unit that is connected to a desktop computer shown in
figure 24. The baseplate was placed in a standard incubator at 37°C for 4 days. The
software used to run the flexcell system is called the Flexcell® FX-5000 software. The
parameters were set to administer a positive pressure of 120 mmHg every second
(equivalent to 60 beats per minute).
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Figure 24: Flexcell FX-5000 setup

3.6

Immunoflorescent Cell Staining and Imaging
After 10 days of incubation the spheroids were rinsed with PBS and fixed with

4% paraformaldehyde for 20 minutes at room temperature. The paraformaldehyde was
aspirated and the cells were rinsed with PBS 3 times. The cells were permeabilized with
0.3% triton in PBS for 10 minutes at room temperature. BSA concentrated at 0.5% along
with 0.5% triton was used to block the cells for 1-2 hours to prevent any non-specific
binding. Alexa Flour® primary rabbit antibody was used in a 1:1 ratio with the blocking
solution which was pipetted onto the cells. The samples were placed on an orbital shaker
for 2 hours at room temperature. The samples were rinsed with PBS 3 times before
proceeding with the secondary antibodies.
To stain for Cx-43, Alexa Flour® mouse anti-rabbit secondary antibodies were
diluted 1:100 and added to the 1:1 blocking solution at 4 uL per mL. Desmin Alexa
Flour® mouse anti-rabbit antibodies were diluted to 1 uL per mL and then added to the
blocking solution at 4 uL per mL. Approximately 500 uL of the antibody solution was
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then added to the wells and covered with aluminum foil on an orbital shaker for 1 hour at
room temperature. The samples were imaged using a fluorescent microscope at 10X
magnification.
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Chapter 4: Results and Discussion
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4.1

Study 1: Measuring Action Potentials in iCell® Cardiomyocytes
In this study both current clamp and voltage clamp configurations were used. The

electrophysiological readings of the voltage clamp configuration can be seen in figure 25
which corresponds to sample 1 in table 2. The first feature present in the graph is what
appears to be an artifact at the 100 ms tick in the graph. This blip is a capacitive transient
current which appears when the membrane immediately experiences a change in polarity
when exposed to a stepwise voltage increase.
Once an immediate change in polarity occurs, a strong negative current follows
due to the large sodium ion influx. Potassium channels open thereafter which accounts
for the repolarization. This sample was recorded three days post plating and it is likely
that ion channels were not fully matured yet resulting in an inability to perform current
clamp recordings thus, samples were re-recorded 10 days post plating.

3.00 nA

2.00 nA

1.00 nA

0.0 A

-1.00 nA

-2.00 nA

-3.00 nA

-4.00 nA

-5.00 nA

100. ms

120. ms

140. ms

160. ms

180. ms

Figure 25: Action potential of iPSC using voltage clamp configuration
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200. ms

After seven days the samples were rerecorded using the same setup as before.
Action potentials were measured and are shown in figures 26-28 corresponding to
samples 2-4 in table 2.
120. mV

80.0 mV

40.0 mV

0.0 V

-40.0 mV

-80.0 mV

400. ms

800. ms

1.20 s

1.60 s

2.00 s

Figure 26: First sample action potential of iPSC
120. mV

80.0 mV

40.0 mV

0.0 V

-40.0 mV

-80.0 mV

100. ms

300. ms

500. ms

700. ms

Figure 27: Second sample action potential of iPSC
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900. ms
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100. ms
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500. ms

700. ms

900. ms

Figure 28: Third sample of action potential of iPSC containing sealant fluid

The graphs seen in figures 26-28 all resemble physiological relevant action
potentials. Each was stimulated over the course of 1 second and each action potential was
recorded within a 200 ms interval. The first sample shown in figure 25 appears to be a
non-spontaneous cardiomyocyte due to the resting memebrane potential being below -80
mV. Conversely, based on the action potential displayed in figure 26, this cardiomyocyte
could be a pacemaker cell as the resting membrane potential lies above 75. It is important
to point out that the scales in each of the graphs are slightly different which would result
in varying peak shapes. While there were not enough samples to conclusively distinguish
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action potentials of pacemaker compared to ventricular cardiomyocytes, it is possible that
each were measured.
The last graph was measured without removing the seal enhancer solution. This
solution contains a high calcium concentration, explaining why the peak in figure 28 is
much broader than the previous graphs as calcium causes sustained contraction in
myocytes.

4.2

Study 2: Measuring Action Potentials in Cytiva® Cardiomyocytes
The action potentials measured in the following graphs all strongly resemble the

action potentials measured from the iPSCs. All graph parameters can be viewed in the
corresponding tables. The graphs shown in figures 29-32 were all stimulated with enough
current to produce a complete action potential. However, in figure 31, measurements of
early stage action potentials recorded.
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-40.0 mV
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1.00 s
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Figure 29: First sample of action potential in a ESC
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Figure 30: Second sample of action potential in a ESC
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Figure 31: Premature action potentials in a ESC

68

1.20 s

1.40 s

60.0 mV

40.0 mV

20.0 mV

0.0 V

-20.0 mV

-40.0 mV

-60.0 mV

-80.0 mV

-100. mV

200. ms

400. ms

600. ms

800. ms

1.00 s

1.20 s

1.40 s

Figure 32: Action potential of ESC with added calcium and cesium

In figure 31 calcium and cesium chloride was added to the extracellular fluid. The
calcium would explain the increased peak interval while the addition of cesium likely
explain the hyperpolarization region expressed around 600 ms. Since potassium channels
are blocked, a higher concentration of sodium will leave the cell resulting in a brief
hyperpolarized region.
4.3

Study 3: Measuring Action Potentials in 2D Co-Cultures
Unfortunately for this study only one measurement was recorded. Both the ESC

and ADSC groups could not be measured. However, one sample was recorded in the coculture group as show in figure 33.
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Figure 33: 2D co-culture action potential sample

The resting membrane potential is around -60 mV which suggests that this could
be a pacemaker cell. Additionally, the beginning stages of a full action potential are
shown as the cell initially was stimulated below the voltage at which a complete action
potential is produced. This is likely an ESC being measured in this sample as none of the
ASC samples showed any signs of containing pacemaker cells. This graph also looks
very similar to figure 32 in which the cell was stimulated just enough to produce the
beginnings of a full action potential.
It is unknown why recordings were unsuccessful in the other groups. Perhaps the
cells adhered and clumped together after removal from the flask. When cells aggregate in
solution it prevents them from sitting properly on the chip and forming a high resistance
seal making patch clamp recording impossible. Furthermore, the cells become less viable
electrically when suspended for prolonged periods in suspension. It is likely that as the
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number of failed attempts increases, the probability of a successful attempt decreases as
the elapsed time between each sample takes approximately 5 minutes and could be
significantly prolonged if electrophysiological measurements are being recorded.
4.4

Study 4: Measuring Electrophysiology of Cardiomyocytes using MEA
Unlike patch clamp, the electrophysiology recordings of the MEA looks much

different and does not produce a similar action potential graph as a result of measuring
the extracellular field potential. Since MEA does not involve breaking into the cell, the
electrodes can only measure the minute changes in ion concentration in the local
extracellular area. Thus, action potential recordings are shown as sharp peaks in the graph
where a change in ion flow can be detected.
In addition, many of the action potentials viewed in the subplots are different
depending on the location of the cell relative to the electrode. Cells that are directly
placed above an electrode and are tightly bound to the surface of the chip are likely to
produce a much stronger action potential. Furthermore, the type of media used will have
an impact on electrophysiological recordings, as media with higher conductivity or
homogeneity will allow for better ion movement and thus more accurate recordings.
The first two figures are subplots of all the electrodes measured, each electrode
corresponding to a different subplot. Many of the subplots show no activity due to the
absence of cells over the electrode. Furthermore, some cells could be seen directly over
some electrodes while some cells barely came into contact with other electrodes,
resulting in varying sized peaks displayed in the figures. The difference between figures
34 and 35 are the scale sizes where the peaks are enlarged in figure 35.
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Figure 34: Action potential recordings of ESCs on all electrodes on MEA

Figure 35: Action potential recordings of ESCs on all electrodes of MEA

Individual action subplots were expanded and enlarged in figures 35 and 36 with
the only difference being scale size. The action potential in peaks in figure 35 at about
350 uV and hyperpolarizes to about -100 uV. If sampling rates were increased, it is
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possible that the action potentials in this study might resemble those taken using patch
clamp. While the shape of the graph could have been altered by increasing the sampling
rate, the magnitude of the peaks would still remain significantly less than what is seen
using patch clamp due to factors discussed previously. Furthermore, these readings prove
that the cells cultured on each of the MEA plates contained cardiac pacemaker cells as
the samples must be self-excitable in order to produce a spontaneous voltage that can be
recorded.

Figure 36: Action potential generated at a single electrode
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Figure 37: Action potential shown at a single electrode

4.5

Study 5: ADSC Differentiation using 3D Spheroids
Both automated and traditional whole cell patch clamp was attempted on the 3D

spheroids however limitations in the patch clamp configurations used for this experiment
prevented measuring any electrophysiological activity. Therefore, we imaged the
spheroids and measured for two specific myocyte markers using immunofluorescence.
Samples were stained for connexin-43 and desmin which are unique cardiomyocyte
markers. Light microscopy images were also taken of each sample group 3 days post
plating to view the cell spreading potential of these spheroids which can be seen in
figures 38-41.

74

Figure 38: ADSC spheroid 3 days post plating treated with mechanical stimuli

Figure 39: ADSC spheroid 3 days post plating treated with mechanical stimuli and AZT

Figure 40: ADSC spheroid 3 days post plating treated with AZT
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Figure 41: Static untreated spheroid 3 days post plating

Immunoflorescence images can be viewed in figures 42-49. The DAPI stain
fluoresces blue and stains the cell nuclei. The Cx-43 and desmin were stained in each
group using a fluorophore which excites at 488 nm producing a green light.

Figure 42: ADSC derived spheroid stained for Cx-43, mechanical group
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Figure 43: ADSC derived spheroid stained for Desmin, mechanical group

Figure 44: ADSC derived spheroid stained for Cx-43, Mechanical+AZT group

Figure 45: ADSC derived spheroid stained for desmin, mechanical+AZT group
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Figure 46: ADSC derived spheroid stained for Cx-43, AZT group

Figure 47: ADSC derived spheroid stained for desmin, AZT group

Figure 48: ADSC derived spheroid stained for Cx-43, control group
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Figure 49: ADSC derived spheroid stained for desmin, control group

As shown in figures 41-48, every image contained either desmin or Cx-43
respectively. Some pictures appear to contain more cardiac markers than others but that
could be due to some images containing spheroids while others were planar cells. Since
the spheroids are highly concentrated regions of cells, the proteins may appear to be more
visible in these areas.
The abundant expression of cardiomyocyte markers in the static groups compared
to other groups is unexpected. It was hypothesized that groups exposed to mechanical and
chemical stimulation would appear to express more Cx-43 and desmin than the control
groups since stem cells cultured similarly to the native physiological environment of the
target cell have shown to more completely differentiate. However, it is not unreasonable
to assume that the control groups would contain these markers as it has been shown that
differentiating ADSCs in 3D spheroids have been shown to produce myocyte like cells. It
is probable that these cells did not fully differentiate into mature cardiomyocytes.
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Furthermore, since ADSCs are harvested from human lipo-aspirate, it is possible that the
ADSCs contained impurities or other cells resulting in positive staining.
Given the presence of gap junctions in these cells it is likely that they would be
able to propagate an electrical signal however it no pacemaker activity was observed
during the course of this experiment. If patch clamp could have been performed, it is
likely that under stimulation, these cells could have produced an action potential
resembling that of a ventricular cardiomyocyte. Future studies could focus on measuring
the electrophysiology of 3D ADSC cultures using the appropriate set up.
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Chapter 5: Conclusion and Future Directions
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The first study using iPSCs was very successful in measuring action potentials
using both current and voltage clamp configurations. Cells were spontaneously
contracting after 10 days and action potentials recorded in this study matched those found
in literature. Similarly, the second study measuring action potentials in ESCs was also
very successful as additional current clamp measurements of premature action potentials
were recorded as well as fully developed action potentials.
The 2D cell co-culture using ADSCs and ESCs had some success although the
results were inconclusive. While action potentials were recorded in the co-culture group,
no electrophysiological readings could be measured in the ESC or ADSC single culture
groups. Since groups containing ESCs were beating spontaneously, the action potential
recorded in the co-culture group was likely an ESC. Additionally, many of the ADSCs
detached from the culture resulting in an insufficient density for using the automated
patch clamp.
Unfortunately the 3D spheroid study was unsuccessful in measuring any electrical
activity however immunofluorescence suggested that the cells began maturing into
cardiomyocytes. While it remains inconclusive if the cells had fully developed into
ventricular cardiomyocytes, it can be stated with certainty that none of the samples
contained mature pacemaker cells as spontaneous contraction was never observed.
Lastly, the MEA study confirmed the results from the ESC patch clamp
experiment in that the ESCs formed spontaneously beating colonies where ion
concentration fluctuations could be measured without any external stimulus.
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Continuing to investigate the electrophysiological potential for differentiated stem
cells is integral is finding a translational tissue engineered approach to various heart
diseases. The studies shown here indicate that currently iPSCs and ESCs are the most
viable sources for obtaining high densities of cardiac pacemaker cells. Conversely,
spontaneous contractile activity was not observed is studies where ADSCs are solely
used. While showing the electrophysiological potential of ADSC derived cardiomyocytes
is well documented, culturing pacemaker cells from ADSCs is still controversial and
more research is needed to develop a reproducible protocol for such.
Although using current techniques it remains difficult to produce a high volume
of pacemaker cells using ADSCs, they remain of high interest throughout the scientific
community due to their availability. While the experiments presented in this thesis were
limited by time and resources, there are many more possible directions that these studies
could continue.
Using spheroids to differentiate ADSCs into cardiomyocytes is extremely difficult
when performing patch clamp. Thus using the same parameters and methods, a 2D
differentiation study using ADSCs would be more convenient in testing the capability of
these cells to contract if provided an appropriate stimulus. Furthermore, providing an
electrical stimulus to ADSCs in culture may be a crucial element in deriving pacemaker
cells. Using a coupled mechanical and electrical stimulus would be optimal as it is
physiologically relevant and is recommended for future studies.
To derive higher volumes of pacemaker cells many studies have suggested that
seeding densities need to be optimized. Unfortunately many of the studies presented here
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were limited by the amount of cells available at the time, thus seeding densities were
oftentimes less than the recommended values. Further insight into varying the cell density
in culture may result in a higher percentage of pacemaker cells, which would be
necessary when developing a tissue engineering solution to cardiac arrhythmias.
In addition to 5-azacytodine, many studies including Planat-Bernard have shown
using 2-metocaptoethanol has been shown to be very successful in differentiating ADSCs
into pacemaker cells. Future studies could compare the efficacy of cardiac differentiation
by comparing groups of 5-azacytidine and 2-mercaptoethanol treated ADSCs. Varying
the concentration of these groups is also important in determining an optimal
concentration as too much may damage the DNA while too little would result in
insufficient inhibition of DNA methylation.
While the work that was presented here was successful in confirming the capacity
for iPSCs and ESCs to differentiate into spontaneously beating cardiomyocytes, it was
inconclusive in determining the cardiomyocyte differentiating ability for ADSCs to
generate. Unfortunately due to the limitations of time and resources many other studies
that could elucidate more on ADSC differentiation were beyond the scope of this project.
Future studies should continue to work on finding ways to better differentiate ADSCs
into pacemaker cell in vitro for use in clinical applications.
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